Syngene International Limited (SYNGENE) Fair Value & Analysis
Healthcare · IN · Market cap ₹177B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +0.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹388.80 – ₹720.01 · fair‑value band ₹130.07 – ₹216.78 · the ₹440.00 price screens above the ₹173.43 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Syngene International Limited (SYNGENE) currently trades at ₹440.00, while our model-based Fair Value estimate is ₹173.43 — implying the stock looks roughly 60.6% overvalued today. We read business quality at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Syngene International Limited generated revenue of ₹37.4B at a net margin of 8.5%. Revenue grew 1.8% year over year. It earns a return on equity of 6.6%. The balance sheet holds a net cash position of ₹3.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Syngene International Limited reported revenue of ₹37.4B in FY2026 versus ₹26.0B in FY2022, a compound +9.5%/yr. Reported net income was ₹3.2B in FY2026, compounding −5.4%/yr from FY2022.
Is SYNGENE fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Syngene International Limited (SYNGENE) undervalued?
What is the fair value of SYNGENE?
What is the quality score of SYNGENE?
What is the revenue of Syngene International Limited (SYNGENE)?
What is the net profit margin of SYNGENE?
Does Syngene International Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.